CVS Health (NYSE:CVS) Price Target Raised to $100.00

06 Nov 2025, 08:10 by Michael Walen · The Markets Daily

CVS Health (NYSE:CVS – Free Report) had its price target upped by TD Cowen from $99.00 to $100.00 in a research report released on Monday morning,Benzinga reports. TD Cowen currently has a buy rating on the pharmacy operator’s stock.

CVS has been the topic of several other research reports. Wall Street Zen downgraded CVS Health from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Mizuho lifted their target price on CVS Health from $76.00 to $88.00 and gave the company an “outperform” rating in a research note on Thursday, October 9th. Barclays lifted their target price on CVS Health from $80.00 to $87.00 and gave the company an “overweight” rating in a research note on Thursday, September 4th. Leerink Partners lifted their target price on CVS Health from $86.00 to $95.00 and gave the company an “outperform” rating in a research note on Thursday, October 16th. Finally, Cantor Fitzgerald lifted their target price on CVS Health from $78.00 to $95.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Two research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $88.82.

Check Out Our Latest Stock Report on CVS

CVS Health Stock Performance

CVS Health stock opened at $78.71 on Monday. CVS Health has a 12 month low of $43.56 and a 12 month high of $85.15. The company has a market cap of $99.92 billion, a PE ratio of 207.14, a P/E/G ratio of 0.87 and a beta of 0.60. The company has a debt-to-equity ratio of 0.83, a current ratio of 0.83 and a quick ratio of 0.62. The company has a fifty day moving average price of $76.90 and a two-hundred day moving average price of $69.27.

CVS Health (NYSE:CVS – Get Free Report) last announced its quarterly earnings results on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.24. The company had revenue of $102.87 billion during the quarter, compared to the consensus estimate of $98.85 billion. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The company’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.09 earnings per share. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. Research analysts expect that CVS Health will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Thursday, October 23rd were issued a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 3.4%. The ex-dividend date was Thursday, October 23rd. CVS Health’s payout ratio is 700.00%.

Insider Buying and Selling at CVS Health

In other news, Director Anne A. Finucane sold 7,500 shares of CVS Health stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the transaction, the director owned 22,156 shares in the company, valued at $1,573,519.12. The trade was a 25.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.22% of the stock is owned by company insiders.

Hedge Funds Weigh In On CVS Health

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its position in CVS Health by 1.7% in the 2nd quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock valued at $8,305,132,000 after buying an additional 2,063,737 shares during the last quarter. Dodge & Cox raised its position in CVS Health by 4.8% in the 1st quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock valued at $4,976,856,000 after buying an additional 3,353,223 shares during the last quarter. State Street Corp raised its position in CVS Health by 1.4% in the 2nd quarter. State Street Corp now owns 58,788,585 shares of the pharmacy operator’s stock valued at $4,055,237,000 after buying an additional 800,414 shares during the last quarter. Geode Capital Management LLC raised its position in CVS Health by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 28,635,233 shares of the pharmacy operator’s stock valued at $1,966,083,000 after buying an additional 675,824 shares during the last quarter. Finally, Invesco Ltd. raised its position in CVS Health by 15.3% in the 2nd quarter. Invesco Ltd. now owns 23,532,479 shares of the pharmacy operator’s stock valued at $1,623,270,000 after buying an additional 3,118,626 shares during the last quarter. Institutional investors own 80.66% of the company’s stock.

About CVS Health

(Get Free Report)